Table 2.
Response to FOLFOX‐4 treatment in patients with different genetic polymorphisms (n = 166)
| Genotypes | Responders (%) | Non‐responders (%) | P‐values |
|---|---|---|---|
| Overall | 70 (42.2) | 96 (57.8) | |
| GSTP1‐105 status | |||
| Ile/Ile (n = 125) | 47 (37.6) | 78 (62.4) | 0.04 |
| Ile/Val or Val/Val (n = 41) | 23 (56.1) | 18 (43.9) | |
| ERCC1‐118 genotype | |||
| C/C (n = 78) | 41 (52.6) | 7 (47.4) | 0.01 |
| C/T or T/T (n = 88) | 29 (33.0) | 59 (67.0) | |
| XPD‐751 status | |||
| Lys/Lys (n = 139) | 64 (46.0) | 75 (54.0) | 0.02 |
| Lys/Gln (n = 27) | 6 (22.2) | 21 (77.8) | |
| TSER 28‐bp polymorphism | |||
| 2R/2R or 2R/3R (n = 56) | 26 (46.4) | 30 (53.6) | 0.43 |
| 3R/3R (n = 110) | 44 (40.0) | 66 (60.0) | |
| Any risk genotype | |||
| Absence (n = 26) | 18 (69.2) | 8 (30.8) | <0.01 |
| Presence (n = 140) | 52 (37.1) | 88 (62.9) | |
Risk genotypes: GSTP1‐105 Ile/Ile, ERCC1‐118 C/T or T/T, and XPD‐751 Lys/Gln. Non‐responders, patients with stable or progressive diseases; responders, patients with complete or partial remission after treatment with FOLFOX‐4.